This study tests two different schedules of the experimental drug FID-007 combined with cetuximab in 46 adults with advanced head and neck cancer that has spread or come back. The goal is to see which dosing works better at shrinking tumors and to check for side effects. Particip…
Phase: PHASE2 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC